COVID-19 infection in a northern-Italian cohort of systemic lupus erythematosus assessed by telemedicine

Cassione et al., Annals of the Rheumatic Diseases, doi:10.1136/annrheumdis-2020-217717, May 2020

HCQ for COVID-19

1st treatment shown to reduce risk in March 2020, now with p < 0.0000000001 from 426 studies, used in 59 countries.

No treatment is 100% effective.
Protocols combine treatments.

Survey of 165 SLE patients, 127 on HCQ. 8 patients with suspected COVID-19 and 4 confirmed cases. No mortality, one ICU case. 7 patients had no symptoms despite contact with a COVID-19 patient.
No adjustment for concomitant medications or severity of SLE. Confounding by indication.
This study is excluded in the after exclusion results of meta-analysis: not fully adjusting for the different baseline risk of systemic autoimmune patients.
OutcomeImprovementEffect · pTreatmentControl
risk of case 49.6% higher · RR 1.50 · p = 0.59 49.6% higherRR 1.50p = 0.59 10 of 127 (7.9%) 2 of 38 (5.3%) treatment 10 of 127 (7.9%), control 2 of 38 (5.3%)

Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates.

Cassione et al., 12 May 2020, retrospective, Italy, peer-reviewed, survey, median age 52.5, 6 authors.
$0 $500 $1,000+ Efficacy vs. cost for COVID-19 treatment protocols c19early.org November 2026 Italy Angola Colombia Kenya Mozambique Myanmar South Africa Peru Philippines Vietnam Japan Argentina Nepal Iran Bangladesh Ethiopia Ghana Germany Mexico South Korea United Kingdom Saudi Arabia Algeria Morocco Yemen Poland Uzbekistan India China Venezuela DR Congo Madagascar Thailand Uganda Egypt Nigeria Taiwan Fiji Zambia Bosnia-Herzegovina Jordan Georgia Switzerland Dominican Republic Bolivia Côte d'Ivoire Eritrea Togo Bulgaria Greece Slovakia Iceland New Zealand Trinidad and Tobago Mongolia Czechia Belarus Israel Haiti North Macedonia Hong Kong Qatar Panama Serbia Italy favored high-profit treatments.The average efficacy of treatments was very low.High-cost protocols reduce early treatment, andforgo complementary/synergistic benefits. More effective More expensive 75% 50% 25% ≤0%
$0 $500 $1,000+ Efficacy vs. cost for COVID-19treatment protocols worldwide c19early.org November 2026 Italy Angola Colombia Kenya Mozambique Myanmar South Africa Peru Philippines Vietnam Japan Argentina Nepal Iran Bangladesh Ethiopia Ghana Germany Mexico South Korea United Kingdom Saudi Arabia Algeria Morocco Yemen Poland Uzbekistan India China Venezuela DR Congo Madagascar Thailand Uganda Egypt Taiwan Fiji Zambia Jordan Georgia Switzerland Dominican Rep. Bolivia Côte d'Ivoire Eritrea Togo Sri Lanka Bulgaria Greece Slovakia New Zealand Trinidad and Tobago Mongolia Czechia Belarus Israel North Macedonia Hong Kong Qatar Panama Serbia Italy favored high-profit treatments.The average efficacy was very low.High-cost protocols reduce early treatment,and forgo complementary/synergistic benefits. More effective More expensive 75% 50% 25% ≤0%
COVID-19 infection in a northern-Italian cohort of systemic lupus erythematosus assessed by telemedicine
Emanuele Bozzalla Cassione, Giovanni Zanframundo, Alessandro Biglia, Veronica Codullo, Professor Carlomaurizio Montecucco, Lorenzo Cavagna
Annals of the Rheumatic Diseases, doi:10.1136/annrheumdis-2020-217717
Handling editor Josef S Smolen Acknowledgements The authors wish to thank Dr Luciano Perotti from the ICU department of our Hospital for his invaluable contribution to the good outcome of the admitted SLE patient.
References
Ferner, Aronson, Chloroquine and hydroxychloroquine in covid-19, BMJ, doi:10.1136/bmj.m1432
Hollander, Carr, Virtually perfect? telemedicine for Covid-19, N Engl J Med, doi:10.1056/NEJMp2003539
Joob, Wiwanitkit, Sle, hydroxychloroquine and NO SLE patients with COVID-19: a comment, Ann Rheum Dis, doi:10.1136/annrheumdis-2020-217506
Mathian, Mahevas, Rohmer, Clinical course of coronavirus disease 2019 (COVID-19) in a series of 17 patients with systemic lupus erythematosus under longterm treatment with hydroxychloroquine, Ann Rheum Dis, doi:10.1136/annrheumdis-2020-217566
Monti, Balduzzi, Delvino, Clinical course of COVID-19 in a series of patients with chronic arthritis treated with immunosuppressive targeted therapies, Ann Rheum Dis, doi:10.1136/annrheumdis-2020-217424
Remuzzi, Remuzzi, COVID-19 and Italy: what next?, Lancet, doi:10.1016/S0140-6736(20)30627-9
DOI record: { "DOI": "10.1136/annrheumdis-2020-217717", "ISSN": [ "0003-4967", "1468-2060" ], "URL": "http://dx.doi.org/10.1136/annrheumdis-2020-217717", "alternative-id": [ "10.1136/annrheumdis-2020-217717" ], "author": [ { "ORCID": "http://orcid.org/0000-0001-6578-6938", "affiliation": [], "authenticated-orcid": false, "family": "Bozzalla Cassione", "given": "Emanuele", "sequence": "first" }, { "ORCID": "http://orcid.org/0000-0001-5042-1282", "affiliation": [], "authenticated-orcid": false, "family": "Zanframundo", "given": "Giovanni", "sequence": "additional" }, { "affiliation": [], "family": "Biglia", "given": "Alessandro", "sequence": "additional" }, { "ORCID": "http://orcid.org/0000-0003-2557-8514", "affiliation": [], "authenticated-orcid": false, "family": "Codullo", "given": "Veronica", "sequence": "additional" }, { "affiliation": [], "family": "Montecucco", "given": "Carlomaurizio", "sequence": "additional" }, { "affiliation": [], "family": "Cavagna", "given": "Lorenzo", "sequence": "additional" } ], "container-title": "Annals of the Rheumatic Diseases", "container-title-short": "Ann Rheum Dis", "content-domain": { "crossmark-restriction": true, "domain": [ "bmj.com" ] }, "created": { "date-parts": [ [ 2020, 5, 23 ] ], "date-time": "2020-05-23T21:15:14Z", "timestamp": 1590268514000 }, "deposited": { "date-parts": [ [ 2021, 5, 13 ] ], "date-time": "2021-05-13T06:11:30Z", "timestamp": 1620886290000 }, "indexed": { "date-parts": [ [ 2024, 4, 8 ] ], "date-time": "2024-04-08T07:53:04Z", "timestamp": 1712562784455 }, "is-referenced-by-count": 77, "issue": "10", "issued": { "date-parts": [ [ 2020, 5, 12 ] ] }, "journal-issue": { "issue": "10", "published-online": { "date-parts": [ [ 2020, 9, 14 ] ] }, "published-print": { "date-parts": [ [ 2020, 10 ] ] } }, "language": "en", "license": [ { "URL": "https://bmj.com/coronavirus/usage", "content-version": "tdm", "delay-in-days": 0, "start": { "date-parts": [ [ 2020, 5, 12 ] ], "date-time": "2020-05-12T00:00:00Z", "timestamp": 1589241600000 } } ], "link": [ { "URL": "https://syndication.highwire.org/content/doi/10.1136/annrheumdis-2020-217717", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking" } ], "member": "239", "original-title": [], "page": "1382-1383", "prefix": "10.1136", "published": { "date-parts": [ [ 2020, 5, 12 ] ] }, "published-online": { "date-parts": [ [ 2020, 5, 12 ] ] }, "published-print": { "date-parts": [ [ 2020, 10 ] ] }, "publisher": "BMJ", "reference": [ { "DOI": "10.1016/S0140-6736(20)30627-9", "article-title": "COVID-19 and Italy: what next?", "author": "Remuzzi", "doi-asserted-by": "crossref", "first-page": "1225", "journal-title": "Lancet", "key": "2021051223100650000_79.10.1382.1", "volume": "395", "year": "2020" }, { "DOI": "10.1136/annrheumdis-2020-217424", "doi-asserted-by": "publisher", "key": "2021051223100650000_79.10.1382.2" }, { "DOI": "10.1136/annrheumdis-2020-217506", "doi-asserted-by": "publisher", "key": "2021051223100650000_79.10.1382.3" }, { "DOI": "10.1136/annrheumdis-2020-217566", "doi-asserted-by": "publisher", "key": "2021051223100650000_79.10.1382.4" }, { "DOI": "10.1056/NEJMp2003539", "doi-asserted-by": "publisher", "key": "2021051223100650000_79.10.1382.5" }, { "key": "2021051223100650000_79.10.1382.6", "unstructured": "Epidemia COVID-19. Available: https://www.epicentro.iss.it/coronavirus/bollettino/Bolletino-sorveglianza-integrata-COVID-19_23-aprile-2020_appendix.pdf" }, { "DOI": "10.1136/bmj.m1432", "doi-asserted-by": "crossref", "key": "2021051223100650000_79.10.1382.7", "unstructured": "Ferner RE , Aronson JK . Chloroquine and hydroxychloroquine in covid-19. BMJ;1:m1432.doi:10.1136/bmj.m1432" } ], "reference-count": 7, "references-count": 7, "relation": {}, "resource": { "primary": { "URL": "https://ard.bmj.com/lookup/doi/10.1136/annrheumdis-2020-217717" } }, "score": 1, "short-title": [], "source": "Crossref", "subject": [ "General Biochemistry, Genetics and Molecular Biology", "Immunology", "Immunology and Allergy", "Rheumatology" ], "subtitle": [], "title": "COVID-19 infection in a northern-Italian cohort of systemic lupus erythematosus assessed by telemedicine", "type": "journal-article", "update-policy": "http://dx.doi.org/10.1136/crossmarkpolicy", "volume": "79" }